Bill Brazell wrote the best commentary on the FDAs decision not to approve tolvaptan in 2013. He links to it in this commentary. Follow the link. It is a do-not-miss editorial. Here he shares his thoughts on REPRISE.
This week, we will discuss the fresh-off-the-press and fresh from KidneyWk REPRISE trial, which was also presented at the late breaking clinical trial session. Join us to discuss the nitty-gritty on Nov 14th and 15th
Join us this week as we discuss guidelines - with a difference. Hypertension, but in children - as the AAP unveiled them recently. The entire manuscript is over 70 pages, so make sure you read this succinct summary from Cathy Quinlan.